Original Article
Clinical efficacy and safety of topiramate high-dose shock therapy in the treatment of children with epilepsy
Chen Zhenhua, Xia Yiru, Wu Naixu
Published 2020-04-25
Cite as China Clin Pract Med, 2020,11(02): 45-47. DOI: 10.3760/cma.j.cn115570-20191230-01400
Abstract
ObjectiveTo analyze the clinical efficacy and safety of topiramate high-dose shock therapy in the treatment of children with epilepsy.
MethodsA total of 86 children with pediatric epilepsy who were admitted to the Pediatrics of Gaoming District People′s Hospital from May 2015 to May 2019 were selected, aged 4 to 12 years old, and the age range was(8.06±0.62)years old.The children were randomly divided into the high-dose treatment group and the low-dose treatment group, with 43 cases in each group.Patients in the high-dose treatment group were treated with high-dose topiramate shock, and patients in the low-dose treatment group were treated with low-dose topiramate shock.Both groups were treated for 12 weeks.Clinical treatment effect, verbal intelligence quotient(VIQ), full intelligence quotient(FIQ)score and adverse reactions(paresthesia, distraction, nausea and dizziness)were compared between the two groups.
ResultsThe clinical effectiveness of the high-dose treatment group[95.3%(41/43)]was significantly higher than that of the low-dose treatment group[69.8%(30/43)], and the difference was statistically significant(P<0.05). There was no significant difference in VIQ and FIQ scores between the two groups of children before treatment(P>0.05); both VIQ[(108.26±6.85)points]and FIQ scores[(109.26±3.64)points]of the high-dose treatment group after treatment was significantly higher than the low-dose treatment group[(96.85±1.62)points, (100.05±2.84)points], and the difference was statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the high-dose treatment group and the low-dose treatment group(P>0.05).
ConclusionHigh-dose topiramate shock treatment for pediatric epilepsy can effectively reduce the number of seizures, improve children′s cognitive function, and less adverse reactions, it is worthy of clinical application.
Key words:
Topiramate; High-dose shock; Pediatric epilepsy; Verbal intelligence quotient; Full intelligence quotient
Contributor Information
Chen Zhenhua
Department of Pediatrics, Gaoming District People′s Hospital of Foshan, Foshan 528500, China
Xia Yiru
Department of Pediatrics, Gaoming District People′s Hospital of Foshan, Foshan 528500, China
Wu Naixu
Department of Pediatrics, Gaoming District People′s Hospital of Foshan, Foshan 528500, China